Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease
Article first published online: 8 SEP 2011
© 2011 John Wiley & Sons A/S
Volume 32, Issue 2, pages 297–302, February 2012
How to Cite
Alkhouri, N., Morris-Stiff, G., Campbell, C., Lopez, R., Tamimi, T. A.-R., Yerian, L., Zein, N. N. and Feldstein, A. E. (2012), Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver International, 32: 297–302. doi: 10.1111/j.1478-3231.2011.02639.x
- Issue published online: 9 JAN 2012
- Article first published online: 8 SEP 2011
- Manuscript Accepted: 7 AUG 2011
- Manuscript Received: 22 FEB 2011
- neutrophil to lymphocyte ratio;
- nonalcoholic fatty liver disease;
- nonalcoholic steatohepatitis;
- noninvasive marker
Nonalcoholic steatohepatitis (NASH), the most severe form of nonalcoholic fatty liver disease (NAFLD), is associated with inflammation and increased oxidative stress. The neutrophil/lymphocyte ratio (N/L) integrates information on the inflammatory milieu and physiological stress.
The aim of this study was to determine the utility of N/L ratio to predict the presence of NASH in patients with NAFLD.
Our cohort consisted of 101 consecutive patients undergoing liver biopsy for clinical suspicion of NAFLD. Patients were divided into two groups: NASH group (n = 50) and not NASH group (n = 51). The stage of fibrosis was measured using a 4-point scale. The total white cell count, neutrophil and lymphocyte counts were recorded, and the N/L ratio was calculated.
The mean age was 49.5 (±10.8) years and the mean BMI was 31.4 (±4.9) kg/m2. Patients with NASH had a higher N/L ratio compared with patients with not NASH [2.5 (1.9–3.3) and 1.6 (1.2–2.0), respectively, P < 0.001]. The N/L ratio correlated with the NAFLD activity score and its individual components (steatosis, inflammation and ballooning P < 0.001). Patients with advanced fibrosis (F3-4) had an elevated N/L ratio [2.9 (2.0–3.9)] compared with patients with fibrosis stage 1–2 [1.8 (1.2–2.2)], P < 0.001. For each one-unit increase in N/L ratio, the likelihood of having NASH increased by 70% and the likelihood of having fibrosis increased by 50%.
The N/L ratio is higher in patients with NASH and advanced fibrosis. This ratio can be used as a novel noninvasive marker to predict advanced disease.